Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Arthritis Rheumatol. 2015 May;67(5):1323-34. doi: 10.1002/art.39061.
Persistent fibroblast activation underlies skin fibrosis in systemic sclerosis (SSc), but the transcriptional and epigenetic mechanisms controlling this process are not well understood. In view of the potent influence of acetylation status governing tissue fibrosis, we undertook this study to investigate the expression of the antiaging deacetylase enzyme sirtuin 1 (SIRT1) in SSc and its effects on fibrotic responses in vitro and in vivo.
Tissue expression of SIRTs was interrogated from publicly available genome-wide expression data sets and by immunohistochemistry. The effects of SIRT1 on modulating fibrotic responses, as well as the underlying mechanisms, were examined in human and mouse fibroblasts in culture and in an experimental fibrosis model in the mouse.
Analysis of transcriptome data revealed a selective reduction of SIRT1 messenger RNA (mRNA) levels in SSc skin biopsy samples as well as a negative correlation of SIRT1 mRNA with the skin score. Cellular SIRT1 levels were suppressed in normal fibroblasts exposed to hypoxia or platelet-derived growth factor and were constitutively down-regulated in SSc fibroblasts. Activation of SIRT1 attenuated fibrotic responses in skin fibroblasts and skin organ cultures, while genetic or pharmacologic inhibition of SIRT1 had profibrotic effects. The antifibrotic effects of SIRT1 were due in part to decreased expression and function of the acetyltransferase p300. In mice, experimentally induced skin fibrosis was accompanied by reduced SIRT1 expression in lesional tissue fibroblasts, and both fibrosis and loss of SIRT1 in these mice were mitigated by treatment with a SIRT1 activator.
SIRT1 has antifibrotic effects, and its reduced tissue expression in patients with SSc might have a direct causal role in progression of fibrosis. Pharmacologic modulation of SIRT1 in these patients therefore might represent a potential treatment strategy.
系统性硬化症(SSc)皮肤纤维化的基础是成纤维细胞的持续活化,但控制这一过程的转录和表观遗传机制尚不清楚。鉴于乙酰化状态对组织纤维化的强大影响,我们进行了这项研究,以调查抗衰老去乙酰化酶 SIRT1 在 SSc 中的表达及其对体外和体内纤维化反应的影响。
从公开的全基因组表达数据集和免疫组织化学中检测 SIRTs 的组织表达。在体外和实验性纤维化模型中,研究了 SIRT1 调节纤维化反应的作用及其潜在机制。
对转录组数据的分析显示,SSc 皮肤活检样本中 SIRT1 信使 RNA(mRNA)水平选择性降低,并且 SIRT1 mRNA 与皮肤评分呈负相关。正常成纤维细胞在暴露于低氧或血小板衍生生长因子时,细胞 SIRT1 水平受到抑制,而 SSc 成纤维细胞则持续下调。SIRT1 的激活减弱了皮肤成纤维细胞和皮肤器官培养物中的纤维化反应,而 SIRT1 的遗传或药物抑制则具有促纤维化作用。SIRT1 的抗纤维化作用部分归因于乙酰转移酶 p300 的表达和功能降低。在小鼠中,实验性诱导的皮肤纤维化伴有病变组织成纤维细胞中 SIRT1 表达减少,而这些小鼠的纤维化和 SIRT1 丢失均通过 SIRT1 激活剂治疗得到缓解。
SIRT1 具有抗纤维化作用,其在 SSc 患者组织中的表达减少可能直接导致纤维化的进展。因此,在这些患者中对 SIRT1 的药物调节可能代表一种潜在的治疗策略。